Annexon Stock

Annexon Current Assets

The Current Assets of Annexon (ANNX) as of Aug 1, 2026 is 242.19 M USD. In the previous year, Current Assets was 316.46 M USD — a change of -23.47% (lower).

Current Assets

242.19 MUSD

YoY

-23.47%

Last updated:

Current Assets of Annexon is 2026 242.19 M USD. Current Assets of Annexon was 2025 316.46 M USD. It decreases by -23.47% lower compared to the previous year.
Access this data via the Eulerpool API

Annexon Stock analysis

What does Annexon do? Annexon Inc is a biopharmaceutical company based in South San Francisco, California. It was founded in 2011 by Doug Love, Ted Love, and Arnon Rosenthal, who had previously worked at major pharmaceutical companies such as Genentech and Novartis. The company's main goal is to develop new treatment options for neurodegenerative diseases, focusing on the development of drugs that target the autophagy process in cells to reduce damage to nerve cells and alleviate symptoms. Annexon Inc has two divisions, Annexon Biosciences and Annexon Clinical, with partnerships with renowned pharmaceutical companies to advance drug development. Its main product is ANX005, a therapeutic antibody protein that targets the role of the complement system in neurodegenerative diseases. Annexon Inc has received multiple awards for its work and innovations and has a dedicated team of scientists and executives committed to improving the lives of people with neurodegenerative diseases. Annexon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Annexon stock

Current Assets of Annexon is 242.19 M USD in 2026.

Access this data via the Eulerpool API

Balance Sheet — Annexon

All Key Metrics — Annexon